Leqvio · DIN 02518376 · 284 mg/1.5 mL · injection solution-1.5mL pre-filled syringe
Limited Use, Reason for Use code 732 requiredMarketed · checked November 19, 2026
StatusLimited Use, Reason for Use code 732 required
Write on scriptReason for Use code 732 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 732
Reason for Use code 732
For the treatment of Heterozygous Familial Hypercholesterolemia (HeFH) in patients 18 years of age or older who meet the following criteria:
1. Definite or probable diagnosis of HeFH using the Simon Broome or Dutch Lipid Network criteria or genetic testing;
AND
2. Unable to reach Low Density Lipoprotein Cholesterol (LDL-C) target (i.e., LDL-C less than 2.0 mmol/L for secondary prevention) or at least a 50% reduction in LDL-C from untreated baseline for primary prevention despite:
A) Confirmed adherence to ezetimibe for at least a total of 3 months in combination with high dose statin (e.g., atorvastatin 80mg or rosuvastatin 40mg);
OR
B) Confirmed adherence to ezetimibe for at least a total of 3 months and inability to tolerate high dose statin defined as:
(i) Inability to tolerate at least 2 statins with at least one started at the lowest starting dose; AND
(ii) For each statin (two statins in total), dose reduction is attempted for intolerable symptom (myopathy) or biomarker abnormality (creatine kinase (CK) greater than 5 times the upper limit of normal) resolution rather than discontinuation of statin altogether; AND
(iii) For each statin (two statins in total), intolerable symptoms (myopathy) or abnormal biomarker (creatine kinase (CK) greater than 5 times the upper limit of normal) changes are reversible upon statin discontinuation but reproducible by re-challenge of statins where clinically appropriate; AND
(iv) One of the following:
(I.) Other known determinants of intolerable symptoms or abnormal biomarkers have been ruled out;
(II.) Patient developed confirmed and documented rhabdomyolysis;
(III.) Patient is statin contraindicated i.e. active liver disease, unexplained persistent elevations of serum transaminases exceeding 3 times the upper limit of normal.
Inclisiran will not be funded when used in combination with proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies.
Treatment with inclisiran should be discontinued if the patient does not meet all of the following:
1. Patient is adherent to therapy.
2. Patient has achieved a reduction in LDL-C of at least 40% from baseline (4-8 weeks after initiation of inclisiran).
3. Patient continues to have a significant reduction in LDL-C (with continuation of inclisiran) of at least 40% from baseline since initiation of PCSK9 inhibitor. LDL-C should be checked periodically with continued treatment with PCSK9 inhibitors (e.g., every 6 months).
Dosing: 284mg administered as a single subcutaneous injection: initially, again at 3 months, followed by every 6 months
Coverage limit:
LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Leqvio · DIN 02518376
Manufacturer: Novartis Pharma Canada Inc.; listing date 2025-10-31
Health Canada: Marketed since 2022-09-26 · brand LEQVIO · ATC C10AX16 INCLISIRAN · form Solution · route Subcutaneous · ingredients INCLISIRAN (INCLISIRAN) 284 MG/1.5ML · company Novartis pharmaceuticals canada inc · schedule Prescription
Leqvio: Formulary list price $2898.90 per unit (the source does not state the unit; exact figure $2898.9048). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02518376)
Source record
DIN 02518376: Leqvio
Raw flags: sec12=Y, sec3=Y
Item: 240692003; group id 311; item number 0686; lccId 00418; manufacturer id NOV
Source form: Inj Sol-1.5mL Pref Syr; strength: 284mg/1.5mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $2898.9048; ministry $2898.9048
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02518376
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100766
Shortage status: not checked (no credentials)